# Biogen to buy China rights to immune disease drug for up to $850M.

*business · news · 2026-04-20 · Seeking Alpha*

## Key points

- Biogen will acquire exclusive Greater China rights for felzartamab from TJ Bio.
- The deal's total value could reach up to $850 million.
- Felzartamab is an antibody therapy targeting several immune-mediated disorders.
- This agreement marks Biogen's entry into the Chinese immune disease treatment market.

**Companies:** Biogen
**Countries:** China, United States

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4576707-biogen-buy-china-rights-immune-disease-drug)

---

Canonical: https://newsio.io/n/e714fe97-ea2a-49e7-b910-b2e095e8d964/biogen-to-buy-china-rights-to-immune-disease-drug-for-up-to-850m
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works